Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR22998: IsoQC inhibitor targeting CD47-SIRPa “Do not eat me” cancer immune checkpoint”
NHRI technology, “DBPR22998: IsoQC inhibitor targeting CD47-SIRP “Do not eat me” cancer immune checkpoint” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing.
DBPR22998 is an orally bioavailable small molecule isoQC inhibitor that modulate CD47-SIRP “Do not eat me” cancer immune checkpoint activity through targeting post translational modification process of CD47 protein synthesis. DBPR22998 demonstrated potent isoQC inhibitory activity in vitro and anti-tumor efficacy in combination with therapeutic antibodies and immune checkpoint inhibitors in vivo. In addition, DBPR22998 did not cause hematological toxicity as anti-CD47 antibody therapeutics in clinical development.
3. Potential collaboration partner qualifications:
(1) be incorporated and approved by law and does not have any record of misconduct or conviction for any offense
(2) better to have related experience and skills for developing The Technology
(3) better to have experience of international collaboration and clinical trial
(4) be willing to provide long-term investment
Please contact to Ms. Wan-Ping Hsieh (email: email@example.com) or Ms. Wen-Chuan Hsieh (email: firstname.lastname@example.org). Address: Technology Transfer and Incubation Center, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 35053, Taiwan.
(1) If The Technology has been exclusively licensed, this announcement will automatically invalid.
(2) NHRI retains the right to modify and terminate this announcement.
(3) For detailed status of The Technology, please contact to the case officer.